BRQ is the most potent human DHODH inhibitor (IC50 = 1.8 nM), with known potential to specifically decrease the proliferation of glioblastoma cells (Xu et al., 1998); and it is in clinical trials for application against COVID-19 and AML (go.drugbank.com/drugs/DB03523). The gene discussed is DHODH; the disease is acute myeloid leukemia.